News Center

Home page

Peak Report

News reports

Jianfeng Pharmaceutical has made clear its key work in the new year.

Release time:

2023-02-22

2022 held on February 19 , Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, and Huang Jinlongfen, deputy general manager of the group company and general manager of the pharmaceutical company, made arrangements for the key work of pharmaceutical company 2023 and put forward specific requirements. 2023 With the adjustment of the national epidemic control policy, the domestic into the post-epidemic period, the pharmaceutical company will focus on

to reduce the first, innovation-oriented, marketing-led, standardized and efficient " work policy, and solidly promote the production and operation management work. In terms of market expansion, the pharmaceutical industry should optimize management and business teams, strengthen process control, purify the market environment, cultivate benchmark markets, and expand Internet marketing; pharmaceutical business should give full play to regional advantages, make full use of government resources, and expand and strengthen subdivision areas; pharmaceutical retail should comply with changes in the market and customer needs, and seek breakthroughs in business philosophy and business ideas; natural products companies continue to give full play to their advantages in quality, technology, information and brand, expand new areas of the market, focus on the development of the domestic ordinary food market, maintain a steady growth in sales volume, and increase the added value of products; Shanghai Beika should find out the changing law of the pesticide market, expand the sales of pesticide products at the best price, and strive to strengthen cooperation with pharmaceutical R & D and production enterprises to achieve differentiated sales.

In terms of new drug development, continue to strengthen communication and coordination between various levels and departments; strengthen communication with drug review and approval departments to improve the speed and success rate of new drug approval; strengthen in-depth cooperation with

CRO

Company to improve new drug research and development capabilities; scientifically formulate product development plans, further clarify the responsibilities of development, production and quality departments, and accelerate the speed of new drug research and development; continue to carry out technical research, continuously optimize process parameters, improve yield, continue to introduce varieties of raw material preparation integration, stimulate the potential of API bases and preparation internationalization projects, increase the introduction and development efforts, enrich the enterprise product line. In terms of the construction and technological transformation of the project, make preparations for the international project to meet the

FDA

on-site inspection. Complete all kinds of acceptance of various construction projects and relevant approval work before putting them into production, and reach the production standard as soon as possible. Increase foreign cooperation, give full play to the advantages of production capacity and increase revenue; Continue to promote various informatization work and continuously improve the informatization and intelligence level of enterprises. In terms of cost control, further optimize the synthesis process of bulk drugs and improve the yield; Further strengthen the control of the preparation production process; Strengthen the coordination of production and marketing, optimize the production organization mode, and reasonably arrange the production cycle; Speed up the work process of photovoltaic power generation projects; Reasonable deployment of personnel to improve work efficiency; Reduce procurement costs and ensure stable supply by increasing suppliers of raw and auxiliary packaging materials.

In terms of internal control management, we will continue to improve the internal control system of the enterprise, improve the operability of the internal control system, and increase the intensity of system assessment; continue to strengthen tax planning and communicate with the tax authorities to keep abreast of policy developments and reduce the risk of tax inspection.

In terms of safety and environmental protection, take the implementation of the new safety production law as an opportunity to increase the publicity and education of laws and regulations; standardize the development of various production and business activities to ensure the safety of personnel and property. In terms of product quality,

, further strengthen self-inspection of

GMP

and GSP , discover potential quality hazards in time, and implement responsibilities; Taking the opportunity of international projects receiving US FDA certification, strengthen staff education and training, and improve professional skills and professional work ability; Attach great importance to pharmacovigilance and adverse reaction monitoring; Strengthen the construction of quality management system, further standardize quality management and quality control behavior. In terms of team building, we should attach importance to the introduction, training and use of talents, so as to provide more platforms for the growth of talents; select young cadres to enrich the management teams at all levels, enhance the vitality of the team, and create a well-trained, dedicated staff team and a United, pragmatic, responsible and capable management team, so as to meet the needs of sustainable development of enterprises. (Reporter

Ni Yingzhen)

More information

The company fully deploys 2018 work

On January 27, the group company held a business analysis meeting to review and summarize the work in 2017, arrange and deploy the work for the new year, and put forward work requirements. At the meeting, various professional companies and directly affiliated enterprises reported on the overall work situation in 2017, focusing on analyzing the existing problems and deficiencies, and proposing corresponding solutions and work plans for 2018. Xiang Chongping, deputy general manager of the group company, systematically combed the current human resources efficiency and human resources development of the company. Chen Tianci, chairman of the board of supervisors, made a report and analysis on the "three reductions and three improvements" and the safety and environmental protection work in 2017. Lan Xiaolong, head of finance, analyzed the risks and challenges currently faced by the company according to the operating data and financial situation of its subordinate enterprises. The functional departments and offices of the headquarters also made a brief report on their annual work. Yu Jianhong, general manager of the group company, made a comprehensive review of the company's operation in 2017, compared and analyzed the main economic indicators of various industrial sectors, and pointed out that looking for new investment and development projects around strategic objectives, promoting the optimization of organizational structure and post setting, significantly improving the level of information management, improving the ability of fund management and tax planning, achieving certain results in scientific and technological innovation and technological transformation, and strengthening marketing management and market expansion, safety and environmental protection work is basically up to standard, training and talent development have achieved new results and other work highlights; at the same time, it summarizes and reflects on the shortcomings in strategic decision-making, management innovation, performance appraisal, market operation, and talent team building. After analyzing the current macroeconomic situation and the future trends of various related industries, Yu Jianhong informed

2020

07-31

Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base

News from our newspaper On January 19, the group company held the second meeting of the tenth board of directors and reviewed and approved the "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical." On the same day, Jianfeng Pharmaceutical signed an agreement to invest in Shanghai North Carolina Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shanghai North Carolina") by acquiring shares and increasing capital. Shanghai Beika is a high-tech enterprise in Shanghai. It has an academician expert workstation and a number of Shanghai high-tech achievements transformation projects. It has won the title of "second prize for scientific and technological progress" in Songjiang District, Shanghai, "patent pilot enterprise" and "enterprise technology center" in Songjiang District, Shanghai. The company has strong research and development capabilities and has obtained 14 patents. At present, its main business is to provide products and customized services for domestic and foreign pharmaceutical companies. The products mainly include Tinib, alkaloids, carbohydrates and other anti-tumor drug intermediates. The customized services are mainly CDMO (contract development and manufacturing) of new drugs and intermediates. Shanghai North Carolina has two wholly-owned subsidiaries, Anhui Changtai Chemical Co., Ltd. (hereinafter referred to as "Changtai Chemical") and Anhui North Carolina Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui North Carolina"). Changtai Chemical is a pesticide manufacturer designated by the Ministry of Industry and Information Technology. It was established in July 2007. It now has three chemical synthesis workshops and a pesticide preparation compounding workshop, with 10 product approvals and 13 patents. Anhui North Carolina was established in December 2016. Its business scope includes the customization, production and sales of chemical raw materials and pharmaceutical intermediates, and the wholesale and retail of chemical raw materials and products (except hazardous chemicals

2020

07-30

Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base

2020

07-31

Jianfeng Pharmaceutical was rated as a provincial trademark brand demonstration enterprise

On December 28, 2017, Zhejiang Administration for Industry and Commerce announced the list of trademark brand demonstration counties (cities, districts), demonstration towns (streets) and demonstration enterprises in Zhejiang Province in 2017. Jianfeng Pharmaceutical Company was identified as a trademark brand demonstration enterprise, and it was also the only enterprise in Jinhua City to enter the list. Peak Pharmaceutical was established in 1998 and obtained the first registered trademark in 1999. Since then, Jianfeng Pharmaceutical has been actively carrying out brand building in accordance with the requirements of the Trademark Law and other laws and regulations, and has set up an intellectual property department to carry out trademark management, rights protection and other activities; it has established a sound trademark management system, strictly in accordance with the provisions of the Trademark Law to supervise and manage the use of trademarks inside and outside the enterprise, and safeguard the legitimate rights and interests of the enterprise. Establish strategic cooperation with professional institutions, for trademark applications, renewals and other work. In recent years, Jianfeng Pharmaceutical has also explored trademark investment, creating value through intangible assets such as trademarks and brands, promoting efficiency improvement, and further expanding corporate influence; at the same time, it has continuously increased investment in new product research and development and technological transformation, and actively Declare various patents to provide strong support for brand building with technological innovation. According to incomplete statistics, Jianfeng Pharmaceutical and its subsidiaries currently have more than 120 valid trademarks, including 1 well-known trademark in China, 2 well-known trademarks in Zhejiang Province, 5 well-known trademarks in Jinhua City, and 2 overseas registered trademarks; Obtained more than 40 domestic and international patents. Trademark is an important part of intellectual property rights, in the knowledge economy, brand effect is increasingly becoming the leading force of economic development.

2020

07-31

Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base

2020

07-31

The company was rated as an advanced unit of the city's focus on talent and love talent.

News from our newspaper On December 11, the Talent Work Leading Group of the Jinhua Municipal Committee of the Communist Party of China commended the advanced units of Jinhua City that value talents and love talents. 36 units including Jianfeng Group won this honor. The selection of advanced units that value talents and love talents is a measure taken by the Jinhua Municipal Party Committee to further create a good atmosphere of focusing on talents and loving talents, fully respect and make good use of the first resource of talents, serve innovation to drive development, and implement the development strategy of strengthening the province with talents and innovation. The enterprises and institutions that have won this honorary title have always regarded talents as the fundamental driving force for development for a long time, regarded the investment of talents as the most effective investment, and integrated the love of talents into the unit culture. Remarkable achievements have been made in gathering talents, achieving talents, transforming and upgrading, and accelerating development. The Jinhua Municipal Party Committee requires the majority of employers to learn from advanced units, vigorously promote the trend of focusing on talents and loving talents, remove the obstacles to the talent development system and mechanism, and in accordance with the requirements of "walking in the forefront and jointly building Jinhua", in order to promote the construction of a modern metropolitan area and accelerate the construction of the province An important growth pole for high-quality development provides talent support and intellectual guarantee. (this newspaper reporter)

2020

07-31

< 1...38 39 40...61 > 跳转到页